Children Long-Acting Growth Hormone Market size is estimated to be USD 1.2 Billion in 2024 and is expected to reach USD 2.5 Billion by 2033 at a CAGR of 8.9% from 2026 to 2033.
South Korea's market for children's long-acting growth hormones has experienced significant expansion in recent years, reflecting a societal emphasis on physical development and a willingness among parents to invest in their children's growth.
In 2019, the market was valued at approximately 140 billion won. By 2024, it is projected to reach around 300 billion won, indicating a doubling in size over five years. This growth is largely attributed to parents' increasing interest in height enhancement for their children, despite the nation's declining birthrate.
Leading domestic pharmaceutical companies have played a pivotal role in this market expansion:
LG Chem's Eutropin: Achieved sales of approximately 150 billion won in 2023, with an anticipated growth exceeding 20% in 2024.
Dong-A ST's Growtropin: Recorded cumulative sales of 88.6 billion won by the third quarter of 2024 and is on track to surpass 100 billion won in annual revenue.
These domestic products now command over 60% of the market share, competing effectively against global brands like Merck's Saizen and Pfizer's Genotropin. While some imported options offer the convenience of weekly dosing, the associated discomfort has led many to prefer local products that require daily injections but are known for their stable supply and suitability for long-term treatment.
Pharmaceutical companies are actively broadening the approved uses of their products and conducting research to enhance convenience and safety. For instance, Growtropin expanded its indications to include Turner syndrome in 2019 and growth failure in children born small for gestational age in 2020. LG Chem has released interim results from a 20-year follow-up study on Eutropin, demonstrating its safety and efficacy.
Emerging competitors are also making strides in the market. Daewoong Pharmaceutical is developing a pain-free growth hormone solution using dissolvable microneedle patch technology, with clinical trials underway. Alteogen is conducting trials in India for ALT-P1, a long-acting growth hormone requiring weekly injections.
Despite the market's growth, concerns persist about misuse. An estimated 70% of sales are non-reimbursed, with many parents seeking treatments not for medical conditions but to enhance their children's height. Industry insiders caution that there is still insufficient research on the long-term effects or potential side effects of extended use in children without medical necessity.
As the demand for children's long-acting growth hormones continues to rise in South Korea, the industry faces the dual challenge of meeting this demand while ensuring the safe and appropriate use of these treatments.
Get an In-Depth Research Analysis of the South Korea Children Long-Acting Growth Hormone Market Size And Forecast [2025-2032]
Pfizer
Novo Nordisk
Eli Lilly
Merck Serono
F. Hoffmann-La Roche
Ferring Pharmaceuticals
Ipsen
LG Life Sciences
Sandoz International
Anhui Anke Biotechnology
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the South Korea Children Long-Acting Growth Hormone Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the South Korea Children Long-Acting Growth Hormone Market
Recombinant Growth Hormones
Biosimilars
Subcutaneous
Intramuscular
Growth Hormone Deficiency
Idiopathic Short Stature
Turner Syndrome
Prader-Willi Syndrome
Chronic Kidney Disease
Infants (0-1 year)
Children (1-12 years)
Adolescents (13-18 years)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Clinics
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ South Korea Children Long-Acting Growth Hormone Market Research Analysis
1. Introduction of the South Korea Children Long-Acting Growth Hormone Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. South Korea Children Long-Acting Growth Hormone Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. South Korea Children Long-Acting Growth Hormone Market, By Type
6. South Korea Children Long-Acting Growth Hormone Market, By Application
7. South Korea Children Long-Acting Growth Hormone Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. South Korea Children Long-Acting Growth Hormone Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/